Edouard J Trabulsi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2901994/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Contrast-Enhanced Ultrasound and Shear Wave Elastography: Novel Methods for the Evaluation of Urethral Stricture Disease. Journal of Urology, 2022, 207, 152-160.	0.2	6
2	Helix: A Digital Tool to Address Provider Needs for Prostate Cancer Genetic Testing in Clinical Practice. Clinical Genitourinary Cancer, 2022, 20, e104-e113.	0.9	7
3	Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile. European Urology Oncology, 2021, 4, 297-300.	2.6	18
4	Setting the Standards: Examining Research Productivity Among Academic Urologists in the USA and Canada in 2019. European Urology Focus, 2021, 7, 489-496.	1.6	4
5	Effects of Contrastâ€Enhanced Ultrasound of Indeterminate Renal Masses on Patient Clinical Management. Journal of Ultrasound in Medicine, 2021, 40, 131-139.	0.8	3
6	Small Cell Bladder Cancer Response to Second-line and Beyond Checkpoint Inhibitor Therapy: Retrospective Experience. Clinical Genitourinary Cancer, 2021, 19, 176-181.	0.9	7
7	Assessment of Prostate Cancer Treatment Among Black and White Patients During the COVID-19 Pandemic. JAMA Oncology, 2021, 7, 1467.	3.4	14
8	Pretest Genetic Education Video Versus Genetic Counseling for Men Considering Prostate Cancer Germline Testing: A Patient-Choice Study to Address Urgent Practice Needs. JCO Precision Oncology, 2021, 5, 1377-1386.	1.5	5
9	Preventing Prostate Biopsy Complications: to Augment or to Swab?. Urology, 2021, 155, 12-19.	0.5	5
10	AUTHOR REPLY. Urology, 2021, 155, 109.	0.5	0
11	EDITORIAL COMMENT. Urology, 2021, 155, 18.	0.5	Ο
12	Outcomes of Active Surveillance for Men With Intermediate Risk Prostate Cancer: A Population-Based Analysis. Urology, 2021, 155, 101-109.	0.5	4
13	Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy. Prostate Cancer and Prostatic Diseases, 2020, 23, 295-302.	2.0	30
14	Questioning the Status Quo: Should Gleason Grade Group 1 Prostate Cancer be Considered a "Negative Core―in Pre-Radical Prostatectomy Risk Nomograms? An International Multicenter Analysis. Urology, 2020, 137, 102-107.	0.5	2
15	Impact of Tumor Regional Involvement on Active Surveillance Outcomes: Validation of the Cumulative Cancer Location Metric in a US Population. European Urology Focus, 2020, 6, 235-241.	1.6	6
16	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. Journal of Clinical Oncology, 2020, 38, 2798-2811.	0.8	170
17	Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. European Urology Oncology, 2020, 3, 544-547.	2.6	52
18	Superb Microvascular Imaging Improves Detection of Vascularity in Indeterminate Renal Masses. Journal of Ultrasound in Medicine, 2020, 39, 1947-1955.	0.8	13

#	Article	IF	CITATIONS
19	Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma. Journal of Urology, 2020, 203, 690-698.	0.2	76
20	Reply by Authors. Journal of Urology, 2020, 203, 697-698.	0.2	0
21	Patientâ€reported outcomes of blueâ€light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre study. BJU International, 2019, 123, 35-41.	1.3	16
22	Prostate Contrast Enhanced Transrectal Ultrasound Evaluation of the Prostate With Whole-Mount Prostatectomy Correlation. Urology, 2019, 133, 187-191.	0.5	13
23	Prostatic Stromal Tumors of Uncertain Malignant Potential. Urology, 2019, 132, e3-e4.	0.5	5
24	Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies. Clinical Cancer Research, 2019, 25, 5623-5637.	3.2	23
25	Incorporating mpMRI biopsy data into established pre-RP nomograms: potential impact of an increasingly common clinical scenario. Therapeutic Advances in Urology, 2019, 11, 175628721988280.	0.9	1
26	First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy. International Journal of Radiation Oncology Biology Physics, 2018, 100, 695-701.	0.4	6
27	VPAC1-targeted PET/CT scan: improved molecular imaging for the diagnosis of prostate cancer using a novel cell surface antigen. World Journal of Urology, 2018, 36, 719-726.	1.2	5
28	Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot Study. Journal of Cancer Education, 2018, 33, 180-185.	0.6	14
29	Initial Experience with Telemedicine at a Single Institution. Urology Practice, 2018, 5, 367-371.	0.2	14
30	Creation of a Novel Digital Rectal Examination Evaluation Instrument to Teach and Assess Prostate Examination Proficiency. Journal of Surgical Education, 2018, 75, 434-441.	1.2	2
31	Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. European Urology, 2018, 74, 107-114.	0.9	54
32	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. Journal of Clinical Oncology, 2018, 36, 414-424.	0.8	155
33	AUTHOR REPLY. Urology, 2018, 121, 196.	0.5	0
34	Long Term Surveillance of Renal Cell Carcinoma Recurrence Following Ablation using 2D and 3D Contrast-Enhanced Ultrasound. Urology, 2018, 121, 189-196.	0.5	11
35	Multi-institution analysis of racial disparity among African-American men eligible for prostate cancer active surveillance. Oncotarget, 2018, 9, 21359-21365.	0.8	12
36	Response to Pembrolizumab in a Patient With Chemotherapy Refractory Bladder Cancer With Small Cell Variant Histology: A Case Report and Review of the Literature. Clinical Genitourinary Cancer, 2017, 15, e521-e524.	0.9	18

EDOUARD J TRABULSI

#	Article	IF	CITATIONS
37	Development of a voided urine assay for detecting prostate cancer nonâ€invasively: a pilot study. BJU International, 2017, 119, 885-895.	1.3	6
38	Prevalence and Characteristics of Patients with Suspected Inherited Renal Cell Cancer: Application of the ACMG/NSGC Genetic Referral Guidelines to Patient Cohorts. Journal of Genetic Counseling, 2017, 26, 548-555.	0.9	9
39	Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PROâ€IMPACT study. Cancer, 2017, 123, 2850-2859.	2.0	66
40	VPAC1 Targeted 64 Cu-TP3805 kit preparation and its evaluation. Nuclear Medicine and Biology, 2017, 51, 55-61.	0.3	4
41	Inherited Mutations in Men Undergoing Multigene Panel Testing for Prostate Cancer: Emerging Implications for Personalized Prostate Cancer Genetic Evaluation. JCO Precision Oncology, 2017, 1, 1-17.	1.5	27
42	Radiographic Kinetics of Sarcomatoid Renal Cell Carcinoma. Urology, 2016, 93, e13-e14.	0.5	0
43	Clinical Influences in the Multidisciplinary Management of Small Renal Masses at a Tertiary Referral Center. Urology Practice, 2016, 3, 468-474.	0.2	1
44	VPAC1 Targeted 64Cu-TP3805 Positron Emission Tomography Imaging of Prostate Cancer: Preliminary Evaluation in Man. Urology, 2016, 88, 111-118.	0.5	21
45	Genomic Classifier Identifies Men With Adverse Pathology After Radical Prostatectomy Who Benefit From Adjuvant Radiation Therapy. Journal of Clinical Oncology, 2015, 33, 944-951.	0.8	196
46	Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia. Molecular Cancer Therapeutics, 2015, 14, 1777-1793.	1.9	42
47	Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. European Urology, 2015, 68, 959-967.	0.9	395
48	Risk factors for biochemical recurrence after robotic assisted radical prostatectomy: a single surgeon experience. BMC Urology, 2015, 15, 27.	0.6	14
49	Contrast-Enhanced Subharmonic and Harmonic Ultrasound of Renal Masses Undergoing Percutaneous Cryoablation. Academic Radiology, 2015, 22, 820-826.	1.3	12
50	Novel Actions of Next-Generation Taxanes Benefit Advanced Stages of Prostate Cancer. Clinical Cancer Research, 2015, 21, 795-807.	3.2	89
51	Jak2-Stat5a/b Signaling Induces Epithelial-to-Mesenchymal Transition and Stem-Like Cell Properties in Prostate Cancer. American Journal of Pathology, 2015, 185, 2505-2522.	1.9	54
52	Treatment of Exophytic Renal Cancer Smaller than 3 cm: Surgery versus Active Surveillance. Journal of Urology, 2015, 193, 16-18.	0.2	3
53	Surgical suturing training with virtual reality simulation versus dry lab practice: an evaluation of performance improvement, content, and face validity. Journal of Robotic Surgery, 2014, 8, 329-335.	1.0	21
54	High dose rate brachytherapy boost for prostate cancer: A systematic review. Cancer Treatment Reviews, 2014, 40, 414-425.	3.4	57

EDOUARD J TRABULSI

#	Article	IF	CITATIONS
55	Genomic Prostate Cancer Classifier Predicts Biochemical Failure and Metastases in Patients After Postoperative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 89, 1038-1046.	0.4	149
56	The effects of fatigue on robotic surgical skill training in Urology residents. Journal of Robotic Surgery, 2014, 8, 269-275.	1.0	5
57	Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Is Safe, Effective, and Efficient Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer: Results of a Multicenter Phase II Study With Molecular Correlates of Response and Toxicity. Journal of Clinical Oncology, 2014, 32, 1895-1901.	0.8	241
58	Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HCPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome Measures. Journal of Clinical Trials, 2012, 02, .	0.1	8
59	Potential for dose escalation in the postprostatectomy setting with intensity-modulated radiation therapy: a dosimetric study using EORTC consensus guidelines for target volume contours. Practical Radiation Oncology, 2011, 1, 105-114.	1.1	11
60	Minimally invasive radical prostatectomy: transition from pure laparoscopic to robotic-assisted radical prostatectomy. Archivos Espanoles De Urologia, 2011, 64, 823-9.	0.1	8
61	Thermal Ablation of Renal Cell Carcinoma: Triage, Treatment, and Follow-up. Journal of Vascular and Interventional Radiology, 2010, 21, S233-S241.	0.2	26
62	Chemotherapy for Penile and Urethral Carcinoma. Urologic Clinics of North America, 2010, 37, 467-474.	0.8	22
63	Preemptive Multimodal Pain Regimen Reduces Opioid Analgesia for Patients Undergoing Robotic-assisted Laparoscopic Radical Prostatectomy. Urology, 2010, 76, 1122-1124.	0.5	73
64	Enhanced Transrectal Ultrasound Modalities in the Diagnosis of Prostate Cancer. Urology, 2010, 76, 1025-1033.	0.5	60
65	Transition from pure laparoscopic to robotic-assisted radical prostatectomy: A single surgeon institutional evolution. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 81-85.	0.8	36
66	A Multi-Institutional Matched-Control Analysis of Adjuvant and Salvage Postoperative Radiation Therapy for pT3-4N0 Prostate Cancer. Urology, 2008, 72, 1298-1302.	0.5	103
67	The addition of robotic surgery to an established laparoscopic radical prostatectomy program: effect on positive surgical margins. Canadian Journal of Urology, 2008, 15, 3994-9.	0.0	19
68	Correlation of pathology with tumor size of renal masses. Canadian Journal of Urology, 2007, 14, 3616-20.	0.0	13
69	New imaging techniques in prostate cancer. Current Urology Reports, 2006, 7, 175-180.	1.0	16
70	New Approaches to the Minimally Invasive Treatment of Kidney Tumors. Cancer Journal (Sudbury, Mass) Tj ETQc	0 0 0 rgBT	/Overlock 10

71	Leukocyte subtypes in electroejaculates of spinal cord injured men. Archives of Physical Medicine and Rehabilitation, 2002, 83, 31-34.	0.5	38	
----	---	-----	----	--